



Title	Evaluation of the risk of metachronous multiple squamous cell carcinoma of the head and neck after transoral surgery based on the genetic polymorphisms of alcohol dehydrogenase 1B and aldehyde dehydrogenase 2
Author(s)	Inoue, Masaki; Shimizu, Yuichi; Taniguchi, Masanobu; Kimura, Yuki; Furuhashi, Hiroto; Dobashi, Akira; Ikeya, Takashi; Goda, Kenichi; Kato, Masayuki; Kato, Mototsugu; Sakamoto, Naoya; Watanabe, Akihito
Citation	Carcinogenesis, 42(10), 1232-1238 https://doi.org/10.1093/carcin/bgab085
Issue Date	2021-10-01
Doc URL	http://hdl.handle.net/2115/86819
Rights	This is a pre-copyedited, author-produced version of an article accepted for publication in Carcinogenesis following peer review. The version of record Masaki Inoue, Yuichi Shimizu, Masanobu Taniguchi, Yuki Kimura, Hiroto Furuhashi, Akira Dobashi, Takashi Ikeya, Kenichi Goda, Masayuki Kato, Mototsugu Kato, Naoya Sakamoto, Akihito Watanabe, Evaluation of the risk of metachronous multiple squamous cell carcinoma of the head and neck after transoral surgery based on the genetic polymorphisms of alcohol dehydrogenase 1B and aldehyde dehydrogenase 2, Carcinogenesis, Volume 42, Issue 10, October 2021, Pages 1232–1238 is available online at: https://doi.org/10.1093/carcin/bgab085 .
Type	article (author version)
File Information	Carcin 42(10) 1232-1238.pdf



[Instructions for use](#)

1 **Manuscript title**

2 Evaluation of the risk of metachronous multiple squamous cell carcinoma of the head and neck
3 after transoral surgery based on the genetic polymorphisms of alcohol dehydrogenase 1B and
4 aldehyde dehydrogenase 2

5 Short title

6 Head and neck cancer and alcohol metabolism

7

8 Masaki Inoue^{1, †}, Yuichi Shimizu^{2, *, †}, Masanobu Taniguchi³, Yuki Kimura³, Hiroto Furuhashi⁴,
9 Akira Dobashi⁴, Takashi Ikeya⁵, Kenichi Goda⁶, Masayuki Kato⁷, Mototsugu Kato⁸, Naoya
10 Sakamoto¹ and Akihito Watanabe³

11 ¹ Department of Gastroenterology and Hepatology, Graduate school of Medicine and Faculty of
12 Medicine, Hokkaido University, Sapporo, Hokkaido, 060-0808, Japan

13 ² Division of Endoscopy, Hokkaido University Hospital, Sapporo, Hokkaido, 060-8648, Japan

14 ³ Department of Otolaryngology Head and Neck Surgery, Keiyukai Sapporo Hospital, Sapporo,
15 Hokkaido, 003-0027, Japan

16 ⁴ Department of Endoscopy, The Jikei University School of Medicine, Minato-ku, Tokyo, 105-
17 8461, Japan

18 ⁵ Department of Gastroenterology, St. Luke's International Hospital, Chuo-ku, Tokyo, 104-8560,
19 Japan

20 ⁶ Department of Gastroenterology, Dokkyo Medical University, Shimotsuga, Tochigi, 321-0293,
21 Japan

1 7 Department of Endoscopy, The Jikei University Katsushika Medical Center, Katsushika-ku,
2 Tokyo, 125-8506, Japan

3 ⁸ Departments of Gastroenterology, National Hospital Organization Hakodate National Hospital,
4 Hakodate, Hokkaido, 041-8512, Japan

5

6 * To whom correspondence should be addressed. Tel: +81 11 611 8111; Fax: +81 11 611 5820;
7 Email: yuichi0996@gmail.com

8 † These authors contributed equally to this work.

9

1 **Abstract**

2 Patients with superficial head and neck squamous cell carcinoma (HNSCC) can be completely
3 treated by techniques of transoral surgery (TOS). The aim of this study was to evaluate the risk
4 of metachronous multiple HNSCC arising after TOS based on alcohol dehydrogenase 1B
5 (ADH1B) and aldehyde dehydrogenase 2 (ALDH2). We registered patients who underwent TOS
6 for superficial HNSCC. Buccal cell samples were obtained by using a cotton swab to examine
7 two single nucleotide polymorphisms in ADH1B and ALDH2 genotyping. We used Cox
8 proportional hazards models to examine the risk of metachronous HNSCC. A total of 198
9 patients who underwent TOS for HNSCC were evaluated. In multivariate analysis, risks for
10 second HNSCC were ADH1B*1/*1 (hazard ratio (HR), 1.88; 95% confidence interval (CI), 1.11-
11 3.19; $P = 0.02$), ALDH2*1/*2 (HR, 2.11; 95% CI, 1.00-5.16; $P = 0.048$), and alcohol consumption
12 before TOS (HR, 1.17; 95% CI, 1.06-1.27; $P = 0.01$). The 5-year incidence rates of second
13 primary HNSCC in the temperance group and the non-temperance group were 20.8% and 46.5%,
14 respectively (HR, 0.54; 95% CI, 0.31-0.92; $P = 0.02$). Cumulative development rates of third
15 HNSCC in the temperance group and non-temperance group at 10 years were 11.3% and 36.1%,
16 respectively (HR, 0.19; 95% CI, 0.03-0.65; $P = 0.006$). ADH1B*1/*1, ALDH2*1/*2, and moderate
17 or heavy alcohol consumption before treatment are independent risk factors of metachronous
18 HNSCC. Since it was shown that temperance decreased the incidences of second and third
19 metachronous HNSCC, advice to discontinue alcohol drinking is necessary.

20 **Summary**

21 Our study showed that ADH1B*1/*1, ALDH2*1/*2, and alcohol consumption before treatment
22 were independent risk factors for metachronous head and neck squamous cell carcinoma
23 (HNSCC). In addition, continuing to drink alcohol increased the incidence of metachronous
24 HNSCC.

1 Introduction

2 Patients with head and neck squamous cell carcinoma (HNSCC) are often diagnosed in an
3 advanced stage, and even if they can undergo curative treatment, an invasive surgical operation
4 such as total laryngectomy that would result in the loss of important functions is usually chosen
5 for treatment [1]. However, recent developments of optical imaging techniques have contributed
6 to an increase in the role of detection of superficial HNSCC that is confined to the subepithelial
7 layer (without muscle layer invasion) [2-4]. Patients with superficial HNSCC can be completely
8 treated by techniques of transoral surgery (TOS), including endoscopic mucosal resection (EMR),
9 endoscopic submucosal dissection (ESD), endoscopic laryngopharyngeal surgery (ELPS), and
10 transoral video-assisted surgery (TOVS), and clinical outcomes after treatment have been
11 reported to be excellent [5-8]. TOS enables preservation of the laryngopharynx and maintenance
12 of the patients' quality of life in terms of avoidance of language disorders, dysphagia, and
13 cosmetic deformities. However, metachronous multiple HNSCC sometimes arises from the
14 preserved laryngopharynx after TOS. In a previous retrospective cohort study, Muto et al.
15 reviewed long-term outcomes of 104 patients with superficial pharyngeal carcinoma after
16 transoral surgery, and they showed that the cumulative development rate of metachronous
17 multiple cancers in the pharynx at 5 years was 22% [6]. Hanaoka et al. conducted a prospective
18 phase II trial including 54 patients with superficial pharyngeal cancer who underwent ESD and
19 reported that the cumulative development rate of metachronous multiple cancers of the pharynx
20 at 3 years was 18.4% [7]. TOS cannot be regarded as a complete curative treatment considering
21 the possibility of metachronous HNSCC; however, there has been no report on evaluation of the
22 risk for metachronous HNSCC after initial treatment.

23 It is well known that alcohol consumption and smoking habits are closely related to the risk for
24 HNSCC [9, 10]. As for the risk of alcohol consumption, acetaldehyde, which is produced from
25 alcohol, has been reported to have carcinogenicity [11, 12]. Acetaldehyde is metabolized by
26 aldehyde dehydrogenase 2 (ALDH2). The allele A (ALDH2*2) of the rs671: G>A variant has a
27 remarkable loss of acetaldehyde metabolizing activity compared with the allele G (ALDH2*1).
28 Drinkers with inactive ALDH2*2 allele, which is one type of genetic polymorphism, are known to

1 be at a high risk for HNSCC [13]. Alcohol dehydrogenase 1B (ADH1B) metabolizes ethanol
2 included in alcoholic drinks, and ADH1B*1/*1, which is one type of genetic polymorphism of
3 ADH1B, was also reported to be associated with HNSCC [14]. These factors are thought to be
4 related to the occurrence of not only initial HNSCC but also metachronous HNSCC. In this study,
5 we evaluated the risk of metachronous multiple HNSCC arising after TOS for initial superficial
6 HNSCC based on the genetic polymorphisms of ADH1B and ALDH2 along with alcohol
7 consumption and smoking habits.

8 **Materials and methods**

9 **Patients**

10 This study was an observational retrospective multicenter study using newly obtained specimens
11 (buccal cell samples) in Japan. We registered patients who underwent TOS for superficial
12 HNSCC. The study subjects had been followed up by annual physical examinations,
13 otolaryngologists' laryngoscopy, and endoscopic examination for at least two years at seven
14 Japanese institutes. The registration was carried out from January 2019 to March 2020. Inclusion
15 criteria for this study were (1) pathological diagnosis of HNSCC in the first resected specimens,
16 (2) complete resection by TOS, (3) written informed consent obtained from the patient, and (4)
17 possibility of collecting buccal cell samples. Exclusion criteria were (1) after total laryngectomy (2)
18 additional surgical resection after TOS, (3) with muscle layer invasion, (4) unsuitability as
19 subjects, (5) age < 20 years, and (6) current pregnancy.

20 Information on past treatment of HNSCC by TOS and histological diagnosis was obtained from
21 medical records. After confirmation of consent, buccal cell samples were obtained by using a
22 cotton swab to examine two single nucleotide polymorphisms in ADH1B and ALDH2 genotyping.

23 This study was carried out according to the principles of the Declaration of Helsinki and was
24 approved by the Medical Ethics and Human Clinical Trial Committee of Hokkaido University
25 Hospital and all participant institutes. The study was registered with the Japanese University
26 Hospital Medical Information Network (UMIN) Clinical Trials Registry (UMIN: 000034980).
27 Written informed consent was obtained from the study subjects at the registration.

1 **Alcohol consumption and smoking habits**

2 The physicians in the participant institutes had advised, in principle, all of the patients to stop or
3 reduce drinking and smoking after treatment. Information on alcohol consumption and smoking
4 before and after TOS was obtained by using a questionnaire. Subjects whose alcohol
5 consumption was less than 1 unit/week were classified as rare drinkers, those whose alcohol
6 consumption was 1 to 8.9 units/week were classified as light drinkers, those whose alcohol
7 consumption was 9 to 17.9 units/week were classified as moderate drinkers, and those whose
8 alcohol consumption was 18 or more units/week were classified as heavy drinkers. We defined 1
9 unit of alcohol as 22 g of ethanol, which is contained in 500 mL of beer or two glasses (200 mL)
10 of wine. Subjects who did not smoke or smoked rarely were classified as rare smokers
11 (nonsmokers). Habitual smokers with a smoking history of < 30 pack years were classified as
12 light smokers, while subjects who had a smoking history of ≥ 30 pack years were classified as
13 heavy smokers. Thirty pack years = one package of cigarettes (20 cigarettes) daily for 30 years
14 [15, 16]. If alcohol consumption and smoking habits varied during the period for evaluation, we
15 registered the average amount of them for statistical analysis.

16 **ADH1B/ALDH2 polymorphisms**

17 SNPs of ADH1B and ALDH2 genes were genotyped using the TaqMan assay on an ABI 7300
18 real-time polymerase chain reaction (PCR) System (Applied Biosystems) [17]. The slow-
19 metabolizing form of ADH1B is encoded by the ADH1B*1 allele, while the inactive form of ALDH2
20 is encoded by the ALDH2*2 allele. We compared ADH1B*1/*1 genotype carriers with ADH1B*2
21 allele carriers and ALDH2*2 allele carriers with ALDH2*1/*1 genotype carriers.

22 **Definitions**

23 Metachronous HNSCC was defined as new HNSCC that was diagnosed more than one year
24 after TOS for the primary HNSCC (New HNSCC that was diagnosed within one year from
25 treatment of the primary HNSCC was defined as synchronous HNSCC.). Second primary
26 HNSCC was metachronous cancer arising after the first primary HNSCC, and third primary
27 HNSCC was metachronous cancer arising after the second primary HNSCC. New HNSCC that

1 was adjacent to a scar of surgical margin-positive HNSCC was defined as local recurrence. In
2 order to evaluate the effectiveness of temperance and smoking cessation for preventing
3 metachronous carcinoma, habitual drinkers and smokers were each divided into two groups.
4 Patients in the non-temperance group were patients who continued to drink alcohol with heavy or
5 moderate consumption after the first TOS, and patients in the temperance group were patients
6 who reduced consumption of alcohol from heavy or moderate consumption to light or rare
7 consumption after the first TOS. Patients in the smoking group were patients who continued with
8 heavy or light smoking after the first TOS, and patients in the nonsmoking group were patients
9 who had been heavy or light smokers and stopped smoking after the first TOS.

10 **Statistical analysis**

11 We examined the risk of metachronous HNSCC. Age is expressed as mean \pm standard deviation
12 (SD). Drinking volume is shown as median and interquartile range (IQR). Differences in
13 frequency distributions were tested using the chi-square test or Fisher's exact test, and
14 quantitative data were examined with Mann-Whitney's U test. Differences were considered
15 statistically significant at $P < 0.05$. The time to development of metachronous HNSCC was
16 defined as the period from the day of TOS to the day of diagnosis of metachronous HNSCC. The
17 Kaplan–Meier method and log-rank test were used for analyzing the development of
18 metachronous HNSCC. We used Cox proportional hazards models on the scale of the time from
19 the first TOS to metachronous HNSCC to estimate hazard ratios (HRs) and 95% confidence
20 intervals (CIs). We conducted univariate analysis, and significant items from univariate analysis
21 were used in multivariate analysis. JMP® Pro 14.0.1 (SAS Institute, Inc., Cary, NC, USA) was
22 used for data analyses.

23 **Results**

24 **Subjects**

25 We enrolled 200 patients who underwent TOS for HNSCC in the study period. One patient was
26 excluded because of a genetic examination error. Another patient was excluded because

1 additional surgical resection was performed in the head and neck region after TOS. A total of 198
2 patients were evaluated.

3 Characteristics of the patients and the first primary HNSCC are shown in Table 1. The median
4 follow-up period at the registration was 54 months (range, 24-184 months). The primary HNSCC
5 locations were the hypopharynx in 157 patients (79.3%), oropharynx in 27 patients (13.6%), and
6 larynx in 14 patients (7.1%). As for methods of TOS, ELPS was performed for 142 patients
7 (71.7%), EMR was performed for 31 (15.7%), ESD was performed for 23 (11.6%), and TOVS
8 was performed for 2 (1.0%). According to the clinical practice guideline committee of Japan
9 Society for Head and Neck Cancer, TOS was performed for patients who were diagnosed to be
10 in clinical N0, M0 stage. No patients died of primary HNSCC during the follow-up period.

11 **Second primary HNSCC**

12 Clinical characteristics of patients with and those without second HNSCC are shown in Table 2.
13 Second HNSCC was detected in 64 patients (32.3%). Patients with second HNSCC were
14 significantly younger than patients without second HNSCC (mean \pm SD age, 61.8 \pm 9.1 and 67.4
15 \pm 7.0 years, respectively; $P < 0.001$). Patients with second HNSCC included a significantly larger
16 proportion of patients with ADH1B*1/*1 (51.6% and 25.4%, respectively; $P < 0.001$) and a
17 significantly larger proportion of patients with ALDH1*1/*2 + *2/*2 (89.1% and 71.6%,
18 respectively; $P = 0.006$). The amount of alcohol consumption before TOS was significantly larger
19 in patients with second HNSCC (median and IQR, 32.3 (23.9-47.2) and 23.4 (14.7-37.3)
20 units/week, respectively; $P = 0.011$), and the amount of alcohol consumption after TOS was also
21 significantly larger in patients with second HNSCC (median and IQR, 15.3 (2.0-31.0) and 7.8 (0-
22 21.5) units/week, respectively; $P = 0.007$). There was no significant difference between the two
23 groups in smoking before and after TOS. The results obtained by using univariate and
24 multivariate Cox proportional hazards models are summarized in Table 3. In multivariate analysis,
25 risks for second HNSCC were ADH1B*1/*1 (HR, 1.82; 95% CI, 1.08-3.10; $P = 0.026$),
26 ALDH2*1/*2 + *2/*2 (HR, 2.11; 95% CI, 1.00-5.17; $P = 0.049$), and alcohol consumption before
27 TOS (HR, 1.15; 95% CI, 1.04-1.28; $P = 0.014$).

1 **Third primary HNSCC**

2 The clinical characteristics of patients with third HNSCC are summarized in Table 4. Third
3 HNSCC was detected in 20 patients (10.1%). Patients with third HNSCC were significantly
4 younger than patients without third HNSCC (mean \pm SD age, 59.0 \pm 6.9 and 66.3 \pm 8.0 years,
5 respectively; $P < 0.001$). Patients with third HNSCC included a significantly larger proportion of
6 patients with ADH1B*1/*1 (65.0% and 30.3%, respectively; $P = 0.002$) and a significantly larger
7 proportion of patients with ALDH1*1/*2 + *2/*2 (95.0% and 75.3%, respectively; $P = 0.049$). The
8 amount of alcohol consumption after TOS was significant larger in patients with third HNSCC
9 (median and IQR, 17.9 (11.8-33.0) and 8.0 (0-23.1) units/week, respectively; $P = 0.005$).
10 Smoking before and after TOS was also not significant for patients with third HNSCC. The results
11 using a univariate Cox proportional hazards model are summarized in Table 5. In univariate
12 analysis, risks for third HNSCC were young age (HR, 0.48; 95% CI, 0.27-0.84; $P = 0.010$),
13 ADH1B*1/*1 (HR, 3.81; 1.56-10.16; $P = 0.003$), ALDH2*1/*2 + *2/*2 (HR, 4.84; 95% CI, 1.00-
14 87.05; $P = 0.049$), and alcohol consumption after the first TOS (HR, 1.36; 95% CI, 1.05-1.70; $P =$
15 0.020). There were no differences in sex, alcohol consumption before the primary TOS, and
16 smoking before and after the primary TOS. The number of third primary HNSCC was not
17 sufficient for multivariate analysis.

18 **Effect of temperance for habitual drinkers and effect of smoking cessation for habitual** 19 **smokers.**

20 Figure 1A and 1B show cumulative incidence curves according to the effect of temperance and
21 effect of smoking cessation based on the development of second primary HNSCC. The 5-year
22 incidence rates of second primary HNSCC after initial TOS in the temperance group and the non-
23 temperance group were 20.8% and 46.5%, respectively (HR, 0.54; 95% CI, 0.31-0.92; $P = 0.02$).
24 Even when the hazard ratio was adjusted for age, sex, ADH1B, ALDH2 and alcohol consumption
25 before TOS, temperance decreased the incidence of second HNSCC (adjusted HR, 0.54; 95%
26 CI, 0.29-0.96; $P = 0.04$). The rate of development of second HNSCC in the nonsmoking group
27 was not significantly different from that in the continuous smoking group. Figure 1C shows
28 cumulative incidence curves according to the effect of temperance based on the development of

1 third primary HNSCC. Cumulative development rates of third HNSCC in the temperance group
2 and non-temperance group at 10 years were 11.3% and 36.1%, respectively (HR, 0.19; 95% CI,
3 0.03-0.65; $P = 0.006$).

4

5 **Discussion**

6 The phenomenon of multiple squamous cell carcinomas arising in the esophagus and head and
7 neck region has been known as the “field cancerization” phenomenon since more than a half a
8 decade ago [18]. Field cancerization is a concept of multiple cancers developing in the mucosal
9 epithelium of the esophagus and head and neck region due to exposure to carcinogens
10 produced by drinking or smoking [18]. Multiple cancers arise not only synchronously but also
11 metachronously, and the risks of their development, especially the risk for metachronous multiple
12 esophageal squamous cell carcinoma (ESCC) after endoscopic resection, have been reported
13 [19, 20]. As for the relationship between alcohol metabolism gene and field cancerization, Abiko
14 et al. reviewed 158 patients with ESCC who underwent endoscopic resection according to the
15 relationship between metachronous cancer and polymorphisms of ADH1B/ALDH2. They
16 concluded that inactive heterozygous ALDH2 and alcohol consumption after treatment were
17 independent risk factors for metachronous ESCC and HNSCC [21]. Our study including patients
18 with HNSCC who underwent TOS showed that ADH1B*1/*1, ALDH2*1/*2, and alcohol
19 consumption before treatment were independent risk factors for metachronous HNSCC. These
20 differences might be explained by direct genetic damage due to exposure of the
21 pharyngolaryngeal mucosa to alcohol. In fact, the IARC Working Group concluded that there is
22 sufficient evidence for the carcinogenicity of ethanol itself [22, 23].

23 HNSCC had been considered as a disease with a poor prognosis, but it has been revealed that a
24 favorable prognosis can be expected if HNSCC is found at an early stage. It was reported that 5-
25 year disease-specific survival rates for patients with superficial HNSCC who underwent TOS
26 were 97%-100% [6, 24]. We therefore consider that early detection of HNSCC and prevention of

1 metachronous HNSCC are very important for maintaining the patient's quality of life after
2 treatment. The head and neck region, especially the hypopharyngeal region, has important roles
3 in swallowing and vocalization. Since the pharynx originally has a narrow lumen, multiple scars
4 caused by repeated TOS would induce swallowing difficulty and aspiration pneumonia. We
5 therefore consider that detection of metachronous HNSCC as early as possible and when its size
6 is small is very important. We recommend that patients who have two or three of the above-
7 mentioned risk factors should undergo detailed follow-up examinations. In addition, our study
8 revealed that continuing to drink alcohol, even in moderate amounts, increased the incidence of
9 not only second primary HNSCC but also third primary HNSCC. Patients would be able to control
10 the amount of drinking by themselves unlike the alcohol metabolism gene. If patients with
11 HNSCC who underwent TOS continue to drink alcohol after treatment, they should be
12 encouraged to reduce alcohol consumption by warning them that continuous drinking leads to
13 economic, social, and physical burdens caused by repeated treatment under general anesthesia,
14 hospital treatment, and deterioration in the quality of life due to organ dysfunctions such as
15 swallowing difficulty. On the other hand, an unexpected result in the present study was that
16 smoking cessation did not influence the development of metachronous HNSCC. As for the
17 effectiveness of smoking cessation for preventing metachronous carcinoma, Katada et al.
18 conducted a prospective study including 330 patients with ESCC who underwent endoscopic
19 resection and their results showed that smoking cessation did not reduce the incidences of
20 metachronous ESCC and HNSCC [25]. Although it is obvious that smoking is one of the most
21 important risk factors, our results suggested that genetic damage when initial HNSCC developed
22 might remain after treatment. Elucidation of the mechanism would require further molecular-
23 biological investigation.

24 Several limitations of this study should be mentioned. First, our study was a retrospective study.
25 We therefore could not evaluate patients who died of other diseases and who dropped out from
26 the follow-up examination. However, since detection of superficial HNSCC requires an advanced
27 diagnostic technique, it would be difficult to collect a sufficient number of cases as a prospective
28 study design and to carry out regular long-term follow-up. Second, in this study, we did not

1 investigate human papillomavirus (HPV) infection, which is known as a significant carcinogenic
2 factor for oropharyngeal cancer [26]. However, HPV-positive oropharyngeal squamous cell
3 carcinoma was reported to be mainly associated with the lateral wall of the oropharynx [27]. In
4 this study, the proportion of patients with cancer in the lateral wall of the oropharynx was only
5 1.5%, and it was therefore considered that the influence of HPV infection was extremely limited.
6 Third, because we simply classified the registered patients according to the average amount of
7 alcohol consumption and smoking habits, detailed variation of them during the period for
8 evaluation (for example, heavy drinking in the former period and abstinence in a later period after
9 treatment) was not evaluated. Fourth, all of the subjects in our study were Japanese. Genetic
10 polymorphisms of alcohol metabolism vary in different ethnic groups and are very different in
11 East Asians and Westerners. It was reported that the frequency of inactive ALDH2*1/*2 allele
12 was less than 5% in Westerners and was 35% in Japanese, whereas the frequency of
13 ADH1B*1/*1 was more than 90% in Westerners and was only 7% in Japanese [28, 29]. Thus, our
14 results regarding the alcohol metabolism gene polymorphism may not be able to be completely
15 applied to other ethnic groups. Further study may therefore be required.

16 In conclusion, ADH1B *1/*1, ALDH2 *1/*2, and amount of alcohol consumption before treatment
17 are independent risk factors of metachronous HNSCC for patients with HNSCC who have
18 undergone TOS. A follow-up examination schedule should be planned on the basis of the above
19 risk factors. Regarding habitual drinkers, since it was shown that temperance decreased the
20 incidences of second and third metachronous HNSCC, advice to discontinue alcohol drinking is
21 necessary.

22

23 **Funding**

24 This work was not supported by any funding agency.

25

1 *Conflict of Interest Statement:* None declared.

2

3 **Data Availability Statement**

4 The data that support the findings of this study are available on request from the corresponding
5 author. The data are not publicly available due to privacy or ethical restrictions.

1 **References**

2 1. Ferlay,J. *et al.* (2019) Estimating the global cancer incidence and mortality in 2018:
3 GLOBOCAN sources and methods. *Int. J. Cancer*, **144**, 1941-1953.

4

5 2. Katada,C. *et al.* (2010) Narrow band imaging for detecting superficial squamous cell
6 carcinoma of the head and neck in patients with esophageal squamous cell carcinoma.
7 *Endoscopy*, **42**, 185-190.

8

9 3. Muto,M. *et al.* (2007) Multicenter prospective randomized controlled study on the detection
10 and diagnosis of superficial squamous cell carcinoma by back-to-back endoscopic examination
11 of narrow band imaging and white light observation. *Gastrointest. Endosc.*, **65**, AB110.

12

13 4. Goda,K. *et al.* (2016) Dual-focus versus conventional magnification endoscopy for the
14 diagnosis of superficial squamous neoplasms in the pharynx and esophagus: a randomized trial.
15 *Endoscopy*, **48**, 321-329.

16

17 5. Shimizu,Y. *et al.* (2006) Endoscopic submucosal dissection for treatment of early stage
18 hypopharyngeal carcinoma. *Gastrointest. Endosc.*, **64**, 255-259.

19

20 6. Muto,M. *et al.* (2011) Long-term outcome of transoral organ-preserving pharyngeal endoscopic
21 resection for superficial pharyngeal cancer. *Gastrointest. Endosc.*, **74**, 477-484.

1

2 7. Hanaoka,N. *et al.* (2015) Endoscopic submucosal dissection as minimally invasive treatment
3 for superficial pharyngeal cancer: a phase II study (with video). *Gastrointest. Endosc.*, **82**, 1002-
4 1008.

5

6 8. Watanabe,A. *et al.* (2017) Synopsis of transoral endoscopic laryngopharyngeal surgery for
7 superficial pharyngeal cancers. *Head Neck*, **39**, 1779-1787.

8

9 9. Yokoyama,A. *et al.* (2001) Alcohol and aldehyde dehydrogenase gene polymorphisms and
10 oropharyngolaryngeal, esophageal and stomach cancers in Japanese alcoholics. *Carcinogenesis*,
11 **22**, 433-439.

12

13 10. Asakage,T. *et al.* (2007) Genetic polymorphisms of alcohol and aldehyde dehydrogenases,
14 and drinking, smoking and diet in Japanese men with oral and pharyngeal squamous cell
15 carcinoma. *Carcinogenesis*, **28**, 865-874.

16

17 11. Seitz,H.K. *et al.* (2007) Molecular mechanisms of alcohol-mediated carcinogenesis. *Nat. Rev.*
18 *Cancer*, **7**, 599-612.

19

20 12. Brooks,P.J. *et al.* (2014) Acetaldehyde and the genome: beyond nuclear DNA adducts and
21 carcinogenesis. *Environ. Mol. Mutagen.*, **55**, 77-91.

1

2 13. Koyanagi, Y.N. *et al.* (2017) Development of a prediction model and estimation of cumulative
3 risk for upper aerodigestive tract cancer on the basis of the aldehyde dehydrogenase 2 genotype
4 and alcohol consumption in a Japanese population. *Eur. J. Cancer Prev.*, **26**, 38-47.

5

6 14. Tsai, S.T. *et al.* (2014) The interplay between alcohol consumption, oral hygiene, ALDH2 and
7 ADH1B in the risk of head and neck cancer. *Int. J. Cancer*, **135**, 2424-2436.

8

9 15. Yokoyama, A. *et al.* (2017) Alcohol abstinence and risk assessment for second esophageal
10 cancer in Japanese men after mucosectomy for early esophageal cancer. *PLoS One*, **12**,
11 e0175182.

12

13 16. Yokoyama, T. *et al.* (2003) Alcohol flushing, alcohol and aldehyde dehydrogenase genotypes,
14 and risk for esophageal squamous cell carcinoma in Japanese men. *Cancer Epidemiol.*
15 *Biomarkers Prev.*, **12**, 1227-1233.

16

17 17. Hayashida, M. *et al.* (2014) Direct detection of single nucleotide polymorphism (SNP) by the
18 TaqMan PCR assay using dried saliva on water-soluble paper and hair-roots, without DNA
19 extraction. *Anal. Sci.*, **30**, 427-429.

20

21 18. Slaughter, D.P. *et al.* (1953) Field cancerization in oral stratified squamous epithelium; clinical
22 implications of multicentric origin. *Cancer*, **6**, 963-968.

1

2 19. Urabe, Y. *et al.* (2009) Metachronous multiple esophageal squamous cell carcinomas and
3 Lugol-voiding lesions after endoscopic mucosal resection. *Endoscopy*, **41**, 304-309.

4

5 20. Urabe, Y. *et al.* (2019) Construction of a risk model for the development of metachronous
6 squamous cell carcinoma after endoscopic resection of esophageal squamous cell carcinoma.
7 *Esophagus*, **16**, 141-146.

8

9 21. Abiko, S. *et al.* (2018) Risk assessment of metachronous squamous cell carcinoma after
10 endoscopic resection for esophageal carcinoma based on the genetic polymorphisms of
11 alcohol dehydrogenase-1B and aldehyde dehydrogenase-2: temperance reduces the risk. *J.*
12 *Gastroenterol.*, **53**, 1120-1130.

13

14 22. Baan, R. *et al.*; WHO International Agency for Research on Cancer Monograph Working
15 Group. (2007) Carcinogenicity of alcoholic beverages. *Lancet Oncol.*, **8**, 292-293.

16

17 23. IARC Working Group on the Evaluation of Carcinogenic Risks to Humans. (2010) Alcohol
18 consumption and ethyl carbamate. *IARC Monogr. Eval. Carcinog. Risks Hum.*, **96**, 3-1383.

19

20 24. Satake, H. *et al.* (2015) Clinical outcome after endoscopic resection for superficial pharyngeal
21 squamous cell carcinoma invading the subepithelial layer. *Endoscopy*, **47**, 11-18.

1

2 25. Katada,C. *et al.* (2016) Alcohol Consumption and Multiple Dysplastic Lesions Increase Risk
3 of Squamous Cell Carcinoma in the Esophagus, Head, and Neck. *Gastroenterology*, **151**, 860-
4 869.

5

6 26. Marur,S. *et al.* (2010) HPV-associated head and neck cancer: a virus-related cancer
7 epidemic. *Lancet Oncol.*, **11**, 781-789.

8

9 27. Hama,T. *et al.* (2014) Prevalence of human papillomavirus in oropharyngeal cancer: a
10 multicenter study in Japan. *Oncology*, **87**, 173-182.

11

12 28. Li,H. *et al.* (2009) Refined geographic distribution of the oriental ALDH2*504Lys (nee 487Lys)
13 variant. *Ann. Hum. Genet.*, **73**, 335-345.

14

15 29. Higuchi,S. *et al.* (1995) Alcohol and aldehyde dehydrogenase polymorphisms and the risk for
16 alcoholism. *Am. J. Psychiatry*, **152**, 1219-1221.

17

18 **TABLE AND FIGURES LEGENDS**

19 **Table 1.** Abbreviations: HNSCC, head and neck squamous cell carcinoma; ADH1B, alcohol
20 dehydrogenase 1B; ALDH2, aldehyde dehydrogenase 2; ELPS, endoscopic laryngopharyngeal
21 surgery; EMR, endoscopic mucosal resection; ESD, endoscopic submucosal dissection; TOVS,

1 transoral video-assisted surgery; PW, posterior wall; AW, anterior wall; LW, lateral wall; UW,
2 upper wall; SEP, subepithelial invasion.

3 **Table 2.** Abbreviations: HNSCC, head and neck squamous cell carcinoma; SD, standard
4 deviation; ADH1B, alcohol dehydrogenase 1B; ALDH2, aldehyde dehydrogenase 2; TOS,
5 transoral surgery; IQR, interquartile range. Heavy, ≥ 18 units/week; Moderate, 9-17.9 units/week;
6 Light, 1-8.9 units/week; Rare, < 1 unit/week (1 unit = 22 g ethanol).

7 **Table 3.** Abbreviations: HR, hazard ratio; CI, confidence interval; ref, reference; ADH1B, alcohol
8 dehydrogenase 1B; ALDH2, aldehyde dehydrogenase 2; TOS, transoral surgery

9 **Table 4.** Abbreviations: HNSCC, head and neck squamous cell carcinoma; SD, standard
10 deviation; ADH1B, alcohol dehydrogenase 1B; ALDH2, aldehyde dehydrogenase 2; TOS,
11 transoral surgery; IQR, interquartile range. Heavy, ≥ 18 units/week; Moderate, 9-17.9 units/week;
12 Light, 1-8.9 units/week; Rare, < 1 unit/week (1 unit = 22 g ethanol).

13 **Table 5.** Abbreviations: HR, hazard ratio; CI, confidence interval; ref, reference; ADH1B, alcohol
14 dehydrogenase 1B; ALDH2, aldehyde dehydrogenase 2; TOS, transoral surgery

15 **Fig. 1. (A)** Cumulative incidence curves according to the effect of temperance based on the
16 development of second primary HNSCC. **(B)** Cumulative incidence curves according to the effect
17 of smoking cessation based on the development of second primary HNSCC. **(C)** Cumulative
18 incidence curves according to the effect of temperance based on the development of third
19 primary HNSCC

20 Abbreviations: HR, hazard ratio; CI, confidence interval; non-temperance group, patients who
21 continued to drink alcohol with heavy consumption (≥ 18 units/week) or moderate consumption
22 (9-17.9 units/week) after transoral surgery; temperance group, patients who reduced drinking
23 alcohol from heavy or moderate to light (1-8.9 units/week) or rare (< 1 unit/week) consumption
24 after transoral surgery; smoking group, patients who continued heavy smoking (≥ 30 pack years)

- 1 or light smoking (1-29 pack years) after transoral surgery; nonsmoking group, patients who had
- 2 been heavy or light smokers and who stopped smoking after transoral surgery.

Tables

Table 1 Characteristics of patients at the registration and first primary HNSCC

	All cases
	(n = 198)
	n (%)
Age (years), median (range)	65.5 (42-86)
Sex (male)	180 (90.9)
Alcohol consumption	
Heavy	141 (71.2)
Moderate	41 (20.7)
Light	11 (5.6)
Rare	5 (2.5)
Smoking	
Heavy	148 (74.7)
Light	40 (20.2)
Rare	10 (5.1)
ADH1B genotype	
*1/*1	67 (33.8)

*1/*2		56 (28.3)
*2/*2		75 (37.9)
ALDH2 genotype		
*1/*1		45 (22.7)
*1/*2		153 (77.3)
*2/*2		0 (0.0)
Treatment methods		
ELPS		142 (71.7)
EMR		31 (15.7)
ESD		23 (11.6)
TOVS		2 (1.0)
Tumor subsites		
Hypopharynx	Postcricoid area	8 (4.0)
	Pyriiform sinus	117 (59.1)
	PW	32 (16.2)
Oropharynx	AW	5 (2.5)
	LW	3 (1.5)
	PW	11 (5.6)

	UW	8 (4.0)
Larynx	Epiglottis	6 (3.0)
	Arytenoid	8 (4.0)
Depth of invasion		
	Carcinoma in situ	113 (57.1)
	SEP	85 (42.9)
	Local recurrence	0 (0)

Table 2. Clinical characteristics of patients according to second HNSCC development.

	Second	Without second	
	HNSCC	HNSCC	<i>P</i>
	(n = 64)	(n = 134)	
Sex (male), n (%)	56 (88.0)	124 (92.5)	0.29
Age (years), means (SD)	61.8 (9.1)	67.4 (7.0)	<0.001
ADH1B genotype, n (%)			
*1/*1	33 (51.6)	34 (25.4)	<0.001
*1/*2 + *2/*2	31 (48.4)	100 (74.6)	
ALDH2 genotype, n (%)			
*1/*2 + *2/*2	57 (89.1)	96 (71.6)	0.006
*1/*1	7 (10.9)	38 (28.4)	
Alcohol consumption before TOS			
Heavy, n (%)	55 (85.9)	86 (64.2)	0.011
Moderate, n (%)	8 (12.5)	33 (24.6)	
Light, n (%)	1 (1.6)	10 (7.5)	
Rare, n (%)	0 (0.0)	5 (3.7)	
units/week, median (IQR)	32.3 (23.4)	23.4 (22.5)	0.011

Alcohol consumption after TOS	Heavy, n (%)	27 (42.2)	41 (30.6)	0.010
	Moderate, n (%)	17 (26.6)	20 (14.9)	
	Light, n (%)	5 (7.8)	31 (23.1)	
	Rare, n (%)	15 (23.4)	42 (31.3)	
	units/week, median (IQR)	15.3 (29.0)	7.8 (21.5)	0.007
Smoking, pack years	Heavy, ≥ 30 , n (%)	52 (81.3)	96 (71.6)	0.198
	Light, 1-29, n (%)	11 (17.2)	29 (21.6)	
	Rare, 0, n (%)	1 (1.6)	9 (6.7)	
Smoking after TOS	Yes, n (%)	19 (29.7)	29 (21.6)	0.22

Table 3. Risk factors of second HNSCC by a Cox proportional hazards model.

	Univariate		Multivariate	
	HR (95% CI)	<i>P</i>	HR (95% CI)	<i>P</i>
Age, per +10 years	0.60 (0.44-0.81)	<0.001	0.85 (0.59-1.22)	0.37
Sex				
Female	1 (ref)	0.052	1 (ref)	0.27
Male	0.44 (0.22-1.01)		0.62 (0.29-1.49)	
ADH1B genotype				
*1/*2 + *2/*2	1 (ref)	<0.001	1 (ref)	0.026
*1/*1	2.44 (1.49-4.00)		1.82 (1.08-3.10)	
ALDH2 genotype				
*1/*1	1 (ref)	0.007	1 (ref)	0.049
*1/*2 + *2/*2	2.62 (1.28-6.31)		2.11 (1.00-5.17)	
Alcohol consumption before	1.17 (1.06-1.28)	0.002	1.15 (1.04-1.28)	0.014
TOS, per +10 units/week				
Alcohol consumption after	1.23 (1.07-1.41)	0.005	1.11 (0.96-1.28)	0.173
TOS, per +10 units/week				

Smoking, pack years	1.00 (0.99-1.01)	0.46	-	-
Smoking after TOS				
No	1 (ref)	0.120	-	-
Yes	1.55 (0.89-2.62)		-	

Table 4. Clinical characteristics of patients according to third HNSCC development.

	Third HNSCC (n = 20)	Without third HNSCC (n = 178)	<i>P</i>
Sex (male), n (%)	17 (85.0)	163 (91.6)	0.40
Age (y), means (SD)	59.0 (6.9)	66.3 (8.0)	<0.001
ADH1B genotype, n (%)			0.002
*1/*1	13 (65.0)	54 (30.3)	
*1/*2 + *2/*2	7 (35.0)	124 (69.7)	
ALDH2 genotype, n (%)			0.049
*1/*2 + *2/*2	19 (95.0)	134 (75.3)	
*1/*1	1 (5.0)	44 (24.7)	
Alcohol consumption before TOS			0.69
Heavy, n (%)	17 (85.0)	124 (69.7)	
Moderate, n (%)	3 (15.0)	38 (21.4)	
Light, n (%)	0 (0.0)	11 (6.2)	
Rare, n (%)	0 (0.0)	5 (2.8)	
units/week, median (IQR)	32.9 (22.7)	25.8 (23.3)	0.48

Alcohol consumption after TOS	Heavy, n (%)	10 (50.0)	58 (32.6)	0.002
	Moderate, n (%)	8 (40.0)	29 (16.3)	
	Light, n (%)	0 (0.0)	36 (20.2)	
	Rare, n (%)	2 (10.0)	55 (30.9)	
	units/week, median (IQR)	17.9 (21.2)	8.0 (23.1)	0.005
Smoking, pack years	Heavy, ≥ 30 , n (%)	17 (85.0)	131 (73.6)	0.61
	Light, 1-29, n (%)	3 (15.0)	37 (20.8)	
	Rare, 0, n (%)	0 (0.0)	10 (5.6)	
Smoking after TOS	Yes, n (%)	5 (25.0)	43 (24.2)	0.93

Table 5. Risk factors of third HNSCC by a Cox proportional hazards model

	Univariate	
	HR (95% CI)	<i>P</i>
Age, per +10 years	0.48 (0.27-0.84)	0.010
Sex		
Female	1 (ref)	0.130
Male	0.34 (0.11-1.46)	
ADH1B genotype		
*1/*2 + *2/*2	1 (ref)	0.003
*1/*1	3.81 (1.56-10.16)	
ALDH2 genotype		
*1/*1	1 (ref)	0.049
*1/*2 + *2/*2	4.84 (1.00-87.05)	
Alcohol consumption before	1.09 (0.90-1.30)	0.36
TOS, per +10 units/week		
Alcohol consumption after	1.36 (1.05-1.70)	0.020
TOS, per +10 units/week		


Smoking, pack years	1.00 (0.98-1.01)	0.49
---------------------	------------------	------

Smoking after TOS


No	1 (ref)	0.90
----	---------	------

Yes	1.07 (0.35-2.80)	
-----	------------------	--

A



No. non-temperance	102	87	40	24	9	6	2	0
No. temperance	80	71	34	23	8	3	1	0

B

No. smoking

48

39

16

11

5

2

0

0

No. nonsmoking

140

125

63

42


17

11

5

1

C



No. non-temperance	102	102	61	42	18	13	7	1
No. temperance	80	80	36	25	12	5	3	0